Preeclampsia: Basic, Genomic, and Clinical

ISBN-13: 9789811338649 / Angielski / Miękka / 2018 / 290 str.

Shigeru Saito

Spis treści

Part 1 Risk factors for preeclampsia.- 1 Risk factors for preeclampsia- Part 2 Genetic background in preeclampsia- 2 Genetic background in preeclampsia.- Part 3 Pathological findings in preeclampsia- 3 Shallow trophoblast invasion and poor vascular remodeling.- Part 4 Pathophysiology of preeclampsia- 4 Immunological maladaptation.- 5 Glucose intolerance and insulin resistance.- 6 Placental adenosine signaling.- 7 Obesity and lipokine.- 8 Autophagy in preeclampsia. 9 Animal models in preeclampsia.- 10 The differencies between early onset and late onset preeclampsia.- Part 5 Predicton of preeclampsia- 11 sFlt-1/PlGF.- 12 Home blood pressure measurement.- 13 micro RNA.- Part 6 Therapy- 14 New therapies for preeclampsia.- 15 Statin therapy for preeclampsia.- 16 Prevension of stroke and eclampsia.- Part 7 The risk for cardiovascular event in preeclamtic cases- 17 The risk for cardiovascular event in preeclamtic cases.

O autorze

Dr. Shigeru Saito,

Professor,

Department of Obstetrics & Gynecology,

University of Toyama, Toyama, Japan

Blurb

This volume is an excellent guide that comprehensively illustrates hypertensive disorders of pregnancy, especially preeclampsia, in both the basic and clinical aspects.

Preeclampsia is a pregnancy-specific multi-organ disorder and a leading cause of maternal and neonatal mortality. The pathophysiology of pregnancy-specific disorders was long unknown, but recently many new findings have been reported from the point of view of pathophysiology. Furthermore, this complication of pregnancy, especially preeclampsia, is a potent risk factor for chronic conditions such as cardiovascular disease, diabetes mellitus, kidney disease, and hypertension.

The book is composed of seven parts including genetic background, pathology,  pathophysiology, and the latest prediction and treatment of preeclampsia. Specific basic topics such as immunological maladaptation, placental adenosine signaling, and new prediction markers are also expounded by experts. Thus it benefits not only obstetricians, pediatricians, nephrologists, diabetologists, and cardiologists, but also immunologists, endocrinologists, geneticists, pathologists, biologists, and molecular biologists who are interested in the treatment of hypertension in pregnancy.